United Therapeutics（UTHR）株式概要
ユナイテッド・セラピューティクス・コーポレーションは、米国内外の慢性疾患および生命を脅かす疾患患者のアンメット・メディカル・ニーズを満たす製品の開発および商業化に取り組んでいる。 詳細
報酬
リスク分析
UTHR リスクチェックを通過した。
UTHR Community Fair Values
Create NarrativeSee what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
United Therapeutics Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$528.47 |
| 52週高値 | US$609.35 |
| 52週安値 | US$272.12 |
| ベータ | 0.58 |
| 1ヶ月の変化 | -3.90% |
| 3ヶ月変化 | -6.82% |
| 1年変化 | 73.55% |
| 3年間の変化 | 115.55% |
| 5年間の変化 | 190.48% |
| IPOからの変化 | 8,572.33% |
最新ニュース
Recent updates
Seeking Alpha • Jul 06
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy
Summary United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved. Risks include FDA approval uncertainty, margin compression, US sales concentration, and significant insider selling, but UTHR’s consistent cash flow and profitability mitigate existential concerns. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 18
UTHR: Respiratory Pipeline And Xenotransplantation Advances Will Drive Future Stock Upside
The analyst fair value estimate for United Therapeutics has been revised from $645 to $750 as analysts incorporate a higher assumed future P/E multiple, along with updated views from recent target changes and ratings shifts across firms. Analyst Commentary Recent Street research on United Therapeutics centers on reactions to clinical updates and refreshed price targets, with several bullish analysts highlighting what they see as upside potential tied to execution on key programs and the company’s valuation framework.
ナラティブ更新 • Jun 04
UTHR: IPF Lung Data Will Drive Future Pulmonary Franchise Repricing
Analysts have adjusted the United Therapeutics fair value estimate to $665.23 from $644.08 to reflect updated views on revenue growth potential, profitability, and a lower assumed future P/E multiple following a series of recent price target changes and ratings moves across the Street. Analyst Commentary Recent research has focused on how clinical trial outcomes and pricing assumptions could affect United Therapeutics' earnings power and the appropriate P/E multiple used in valuation models.
ナラティブ更新 • May 17
UTHR: Soft Mist Inhaler Shift Will Pressure Pulmonary Hypertension Expectations
Narrative Update The updated analyst price target for United Therapeutics has edged down by $3 to $516, as analysts factor in a mix of slightly lower projected revenue growth, higher expected profit margins, and a reduced future P/E multiple, following a wave of recent target hikes and one trim across the Street. Analyst Commentary Recent research on United Therapeutics is mixed.ナラティブ更新 • Apr 28
UTHR: IPF And Pulmonary Hypertension Data Will Drive Balanced Future Expectations
Analysts lifted their fair value estimate for United Therapeutics to $519 from $471, citing updated assumptions around revenue growth, profit margins, and future P/E multiples. These updates were informed by a wave of higher Street price targets following encouraging IPF and pulmonary hypertension data and the planned soft mist treprostinil inhaler launch.ナラティブ更新 • Apr 14
UTHR: IPF Lung Data Will Shape Future Pulmonary Franchise Outlook
Analysts have lifted the implied fair value estimate for United Therapeutics from about $592 to roughly $644, as higher Street price targets supported by more constructive views on Tyvaso, ralinepag and TreSMI, and a slightly richer assumed future P/E multiple, feed into modestly stronger revenue growth and margin assumptions. Analyst Commentary Street research around United Therapeutics has turned more constructive, with several bullish analysts revisiting their models following clinical updates on ralinepag and the TETON-1 study, along with the introduction of the TreSMI soft mist inhaler and management's longer term revenue ambitions.ナラティブ更新 • Mar 31
UTHR: Pulmonary Fibrosis Promise Will Ultimately Fall Short Of Expectations
United Therapeutics' analyst fair value estimate has shifted from $423 to $471 as analysts factor in recent TETON-1 and ralinepag data, updated profit margin assumptions, and a modestly higher future P/E. Analyst Commentary Street research around United Therapeutics has become more focused on the readthrough from TETON-1 in idiopathic pulmonary fibrosis, the Phase 3 ralinepag results in pulmonary arterial hypertension, and the planned soft mist inhaler for treprostinil.ナラティブ更新 • Mar 16
UTHR: IPF And PAH Data Plus New Inhaler Will Shape Outlook
The analyst fair value estimate for United Therapeutics has been raised from $572.00 to $592.25 as analysts factor in higher assumed revenue growth, slightly stronger profit margins, and supportive Street research that highlights upcoming idiopathic pulmonary fibrosis and pulmonary arterial hypertension catalysts, as well as the planned soft mist treprostinil inhaler. Analyst Commentary Recent Street research around United Therapeutics clusters around two big themes, the pulmonary arterial hypertension and idiopathic pulmonary fibrosis pipeline, and the shift toward next generation treprostinil delivery, including the soft mist inhaler.ナラティブ更新 • Mar 02
UTHR: Ralinepag Phase 3 Success And New Inhaler Will Drive Upside
Narrative Update: United Therapeutics (UTHR) The updated analyst price target for United Therapeutics has moved from $531.25 to $572.00. This reflects analysts' higher conviction in ralinepag following stronger than expected Phase 3 data, as well as the potential long term contribution from the planned treprostinil soft mist inhaler program.ナラティブ更新 • Feb 16
UTHR: Organ Manufacturing And Sector M&A Capital Will Support Future Upside
United Therapeutics' analyst price target edges higher to $645 from $600, as analysts point to a slightly higher fair value estimate of about $531 per share and a modestly adjusted future P/E assumption around 14x, even as they flag ongoing sector level capital and M&A crosscurrents. Analyst Commentary Analysts are updating their views on United Therapeutics as they reset expectations for both the company and the broader Biotech sector heading into 2026.ナラティブ更新 • Feb 02
UTHR: Organ Manufacturing Pipeline And Sector M&A Prospects Will Drive Future Upside
Analysts have nudged their price target higher for United Therapeutics, with updated assumptions pointing to a fair value of about $530.84 per share versus roughly $518.25 previously, supported by slightly higher projected revenue growth and a modestly richer future P/E multiple. Analyst Commentary Recent commentary has focused on what United Therapeutics might look like as the Biotech sector heads into 2026 with cautious optimism.ナラティブ更新 • Jan 19
UTHR: Respiratory Franchise Execution And Xenotransplantation Progress Will Drive Future Upside
Analysts have raised their price target on United Therapeutics to US$645 from US$575, citing stronger expectations for Tyvaso and Yutrepia revenue, higher projected revenue growth and profit margins, and a lower assumed future P/E multiple, even with a slightly higher discount rate. Analyst Commentary Recent Street research on United Therapeutics has leaned positive, with several bullish analysts lifting their price targets and pointing to execution on key respiratory drugs as a central theme.ナラティブ更新 • Jan 05
UTHR: Pulmonary And IPF Pipeline Momentum Will Support Balanced Future Prospects
Analysts have lifted their blended price targets for United Therapeutics into a roughly US$525 to US$587 range, largely reflecting confidence in Tyvaso-driven Q3 revenue momentum, early Yutrepia uptake, and expectations that the broader pulmonary and IPF franchises and partnership optionality can support the company’s long-term earnings profile. Analyst Commentary Street research around United Therapeutics is clustered around higher price targets in the US$525 to US$587 range, with one firm trimming its target slightly while staying on the sidelines.ナラティブ更新 • Dec 15
UTHR: Future Pulmonary Fibrosis Upside Will Prove Overestimated
We are raising our fair value estimate for United Therapeutics to $423 per share from $320.81, as analysts lift price targets following another record Tyvaso quarter, a strong early Yutrepia launch, and growing conviction that pulmonary fibrosis and ex U.S. partnership opportunities can materially accelerate revenue growth and support higher long term margins. Analyst Commentary Street research following the latest quarter has been broadly constructive, with several firms lifting price targets on the back of record Tyvaso performance and a better than expected Yutrepia launch.ナラティブ更新 • Dec 01
UTHR: Resilient Core And Clinical Milestones Will Support Balanced Prospects Ahead
The analyst price target for United Therapeutics has increased by $5 to reflect continued strong Tyvaso performance, a robust IPF opportunity, and a resilient core business, according to analysts. Analyst Commentary Recent updates from Wall Street reflect a dynamic range of sentiment regarding United Therapeutics, with several notable price target adjustments following the latest quarterly results and clinical developments.ナラティブ更新 • Nov 17
UTHR: Record Clinical Data And Expanding Pipeline Will Support Balanced Outlook Ahead
United Therapeutics’ analyst price targets have increased, with the fair value estimate rising from $510.77 to $513.00. Analysts point to strong Tyvaso revenue growth, robust product launches, and long-term opportunities in idiopathic pulmonary fibrosis.ナラティブ更新 • Oct 31
UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets
United Therapeutics' analyst price target has increased from approximately $493 to $511, as analysts cite strong Tyvaso revenue growth, robust product launches, and positive trial data. These factors support improved profit expectations and future growth prospects.ナラティブ更新 • Oct 17
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
The analyst price target for United Therapeutics has increased modestly by approximately $8 to $492.85. Analysts cite greater confidence in the company’s future sales and profit margins following recent positive clinical trial outcomes and updated research coverage.ナラティブ更新 • Oct 03
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.ナラティブ更新 • Sep 18
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.分析記事 • Sep 03
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement
United Therapeutics Corporation ( NASDAQ:UTHR ) shareholders would be excited to see that the share price has had a...ナラティブ更新 • Sep 03
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.Seeking Alpha • Feb 25
United Therapeutics: A Unique Business With High Margins And Expansion Potential
Summary United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion. Despite risks from patent expirations and legal challenges, UTHR's diversified portfolio and strong financials position it well for sustained growth. Read the full article on Seeking Alpha株主還元
| UTHR | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -1.3% | -0.5% | -2.0% |
| 1Y | 73.6% | 29.7% | 15.1% |
業界別リターン: UTHR過去 1 年間で29.7 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: UTHR過去 1 年間で15.1 % の収益を上げたUS市場を上回りました。
価格変動
| UTHR volatility | |
|---|---|
| UTHR Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: UTHR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: UTHRの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 1,400 | Martine Rothblatt | www.unither.com |
ユナイテッド・セラピューティクス・コーポレーションは、米国内外の慢性疾患および生命を脅かす疾患患者のアンメット・メディカル・ニーズを満たす製品の開発および商業化に取り組んでいる。同社は、プレフィルドカートリッジおよびシングルユースカートリッジによる吸入ドライパウダー製剤Tyvaso DPI、超音波ネブライザーによる吸入液剤Nebulized Tyvaso、肺動脈性肺高血圧症患者を治療し、運動に伴う症状を軽減するRemodulin（トレプロスチニル）注射剤を提供している；トレプロスチニルの錠剤であり、PAH患者の疾患進行を遅延させ、運動能力を向上させるオレニトラム、PAH患者の運動能力を向上させる経口PDE-5阻害薬アドシルカ。また、高リスクの神経芽腫に対するモノクローナル抗体であるUnituxin（ジヌツキシマブ）注射剤、レモジュリンのポンプとコントローラーが分離されたRemunity Pumpの販売も行っている。さらに、PAH治療薬であるRemunityPRO PumpとRalinepag、特発性肺線維症治療薬であるNebulized Tyvaso、開発段階の臓器製品である異種移植片の開発にも携わっている。さらに、肺移植用のEVLP/SLES、異種移植用の開発段階の遺伝子編集ブタの腎臓と心臓であるUKidney、UHeart、UThymoKidney、同種再生医療用のULobe、自家再生医療用のULung、自家再生医療用のIVIVA Kidney、同種再生医療用のmiroliver、同種再生医療用のmirokidneyなどの前臨床製品を提供している。また、DEKA Research & Development Corp.とはトレプロスチニルの皮下投与用の半使い捨てシステムの開発、MannKind Corporationとはトレプロスチニル吸入粉末およびドリームボート装置の開発およびライセンス、Arena Pharmaceuticals, Inc.とはラリネパグの開発に関するライセンスおよび提携契約を結んでいる。同社は1996年に設立され、メリーランド州シルバースプリングに本社を置いている。
United Therapeutics Corporation 基礎のまとめ
| UTHR 基礎統計学 | |
|---|---|
| 時価総額 | US$22.48b |
| 収益（TTM） | US$1.29b |
| 売上高(TTM) | US$3.17b |
17.4x
PER（株価収益率7.1x
P/SレシオUTHR は割高か？
公正価値と評価分析を参照収益と収入
| UTHR 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.17b |
| 売上原価 | US$425.30m |
| 売上総利益 | US$2.74b |
| その他の費用 | US$1.46b |
| 収益 | US$1.29b |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 05, 2026
| 一株当たり利益（EPS） | 30.33 |
| グロス・マージン | 86.58% |
| 純利益率 | 40.61% |
| 有利子負債／自己資本比率 | 0% |
UTHR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/24 21:30 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
United Therapeutics Corporation 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。33
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |